Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910640 | 0.84 | THRB (0.40) | THRB | |
| SCHEMBL1784201 | 0.83 | LMNA (0.37) | — | |
| SCHEMBL10869608 | 0.80 | — | — | |
| SCHEMBL15204260 | 0.80 | THRB (0.52) | THRB | |
| SCHEMBL28339484 | 0.79 | — | — | |
| SCHEMBL3976860 | 0.79 | — | — | |
| SCHEMBL28231406 | 0.79 | THRB (0.35) | THRB | |
| SCHEMBL1408401 | 0.78 | THRB (0.43) | THRB | |
| SCHEMBL11386579 | 0.77 | THRB (0.39) | THRB | |
| SCHEMBL2361319 | 0.77 | THRB (0.48) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | claimed |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | CUREVAC AG (DE) | 2019-10-15 | — | — | US | claimed |
| CN-101874112-B | Formula (I) especially as immunostimulant/adjuvant: GlXmGn or formula (II): the nucleic acid of ClXmCn | 库瑞瓦格股份公司 | 2016-08-24 | — | — | CN | claimed |
| US-8716253-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20130121988-A1 | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | CUREVAC GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| US-8202850-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20120107303-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | IDERA PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | claimed |
| US-8030462-B2 | Immunotherapy; induce immunology response | IDERA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-20110229456-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | IDERA PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | claimed |
| EP-2363141-A1 | Compsition comprising two oligonucleotides linked directly at their 3'ends wherein at leat one oligonucleotide has an accessible 5'end and the compound further comprising IL-2 used for synergistically stimulating an immune response in a patient. | Idera Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | claimed |
| EP-1628531-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2005-02-03 | — | — | US | claimed |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | HYBRIDON, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2004-12-30 | — | — | US | claimed |
| WO-2004103301-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2002-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | TLR3, TLR9, CD47 | THRB 3224/4885 |
| US-20130121988-A1 | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | TLR9, POLN, TLR5 | THRB 3346/4885 |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | IFNG, ICOS, IL2 | THRB 4665/4885 |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | THRB 2957/4885 |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | THRB 4715/4885 |
| US-20120107303-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | CD74, CD47, DCLRE1B | THRB 3372/4885 |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | THRB 2957/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | THRB 4616/4885 |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | TLR9, TLR3, TLR5 | THRB 3508/4885 |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | THRB 2957/4885 |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | TLR9, TLR7, GMNN | THRB 3625/4885 |
| US-20110229456-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | TLR5, TLR3, TLR9 | THRB 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.